Chameleon Biosciences Appoints Silicon Valley Scientist and Entrepreneur, Dr. Thomas Chalberg, to Board Position

$ADVM
$ONCR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Medicinal Chemicals and Botanical Products
Health Care
Get the next $ADVM alert in real time by email

BERKELEY, CA / ACCESSWIRE / January 5, 2022 / Chameleon Biosciences Inc., a company developing the EVADERTM platform to produce next-generation gene therapies that are more potent and less immunogenic, announces today the appointment of Dr. Thomas Chalberg as Independent Board Director. Dr. Chalberg will provide crucial expertise in strategic growth as well as in gene therapy product development.

Dr. Chalberg is a scientist, entrepreneur, and executive in Silicon Valley. He has spent the past 15 years developing novel therapies and life-changing products, particularly in the areas of oncology and ophthalmology. He has been recognized by the World Economic Forum as a Technology Pioneer, by Allicense for 'Breakthrough Deal of the Year,' and by the Foundation Fighting Blindness for his pioneering contributions to research and development.

"Tom is a rare individual who has successfully founded, led, and exited several companies including gene therapy companies," said Genine Winslow, founder and CEO, Chameleon Biosciences. "I am very pleased to have access to Tom's knowledge and advice and very much look forward to working with him to grow Chameleon."

Dr. Chalberg was Founder and CEO of SightGlass Vision which was recently acquired by a joint venture between CooperVision and EssilorLuxottica. Previously, he was COO of Oncorus, Inc. (NASDAQ:ONCR); and Founder/CEO of the gene therapy company Avalanche Biotechnologies ((now Adverum Biotechnologies, NASDAQ:ADVM).

Dr. Chalberg holds a bachelor's degree in Biochemical Sciences from Harvard University, a Ph.D. in Genetics from Stanford University School of Medicine, and a Master of Business Administration from the UC Berkeley Haas School of Business.

"It is an honor to join Chameleon's board of directors and help CEO Genine Winslow and the team advance its EVADER technology and build a pipeline of innovative products," said Dr. Chalberg. "Immune-modulation may play a critical role in the development of many types of gene therapy products, and I have enjoyed learning about Chameleon's unique platform."

LINK to images: Press Kit

About Chameleon Biosciences

Chameleon Biosciences is a Berkeley-based biotech developing next-generation adeno-associated virus (AAV) vectors that have been shown to elicit less immune response in animal models compared to standard AAV, for potentially safer gene therapies with resistance to neutralizing antibodies, repeat dosing and superior efficacies in clinical applications. EVADER technology can be applied to any existing AAV gene therapy to potentially increase the number of treatable patients and to generate novel gene therapies to treat diseases with unmet needs. The company's founder and CEO Genine Winslow is an alumnus of the SkyDeck global accelerator at UC Berkeley. For more information, visit www.chameleonbiosci.com.

Media Contact:

Erica Zeidenberg
Hot Tomato Marketing
erica@hottomato.net
925-518-8159 mobile
925-631-0553 office

EVADER is a trademark of Chameleon Biosciences, Inc.

SOURCE: Chameleon Biosciences Inc.



View source version on accesswire.com:
https://www.accesswire.com/680985/Chameleon-Biosciences-Appoints-Silicon-Valley-Scientist-and-Entrepreneur-Dr-Thomas-Chalberg-to-Board-Position

Get the next $ADVM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADVM
$ONCR

CompanyDatePrice TargetRatingAnalyst
6/25/2024$25.00Outperform
Oppenheimer
4/30/2024$30.00Buy
H.C. Wainwright
7/7/2022$4.00Hold → Buy
Truist
7/23/2021Hold → Neutral
Cantor Fitzgerald
7/23/2021$23.00 → $3.00Overweight → Neutral
Cantor Fitzgerald
7/23/2021$5.00 → $2.00Market Perform
SVB Leerink
More analyst ratings

$ADVM
$ONCR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

    REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Cowen 45th Annual Healthcare Life Sciences Conference on Tuesday, March 4 at 11:50 a.m. ET. The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum's website. A replay of the webcast will be available on the website for at least 30 days following the event. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ:ADVM) is a clinical-stage company that

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

    REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, at 4:40 p.m. ET. The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum's website. A replay of the webcast will be available on the website for at least 30 days following the event. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ:ADVM

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that on December 4, 2024, the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 68,640 shares of common stock and restricted stock units (RSUs) for 34,920 shares of common stock to 13 new employees under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $6.00 per sh

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ADVM
$ONCR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ADVM
$ONCR
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ADVM
$ONCR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ADVM
$ONCR
SEC Filings

See more

$ADVM
$ONCR
Leadership Updates

Live Leadership Updates

See more
  • Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

    - 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones. "We remain laser focused on initiating

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

    REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injec

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

    - 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173.8 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reporte

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ADVM
$ONCR
Financials

Live finance-specific insights

See more
  • Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

    REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Res

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

    - Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

    REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. "We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting" stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "We recently received confirmation that ou

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ADVM
$ONCR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more